Clinical trial · no report yet · Phase 3
DESTINY-Breast11
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
- NCT05113251 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 87 | |
| YouTube | 84 | |
| Podcasts | 52 | |
| X videos | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Neoplasms; Breast Cancer; HER2-positive Early Breast Cancer
- Interventions
- Trastuzumab Deruxtecan; Paclitaxel; Trastuzumab; Pertuzumab; Doxorubicin; cyclophosphamide
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Active comparator
- Enrollment
- 927
- Primary outcomes
- Rate of Pathologic Complete Response (pCR).
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Oct 25, 2021
- Primary completion
- Mar 12, 2025
- Results posted
- Yes
- Registry record
- NCT05113251 · updated Aug 11, 2026